舒必利治疗首发精神分裂症的性别差异

The Gender Differences of the Sulpiride in the Treatment of First-onset Schizophrenia.

目的了解抗精神病药物对男女精神分裂症患者是否存在性别差异。方法对71例首发精神分裂症患者以不同性别进行分组,应用舒必利治疗,以阳性症状和阴性症状量表(PANSS)、副反应量表(TESS)评定疗效及不良反应,在治疗前及治疗后第1、2、4、6、8周末各评定1次。结果两组患者治疗后与治疗前的PANSS评分比较差异有显著性(P<0.0或P<0.01),男性平均用药剂量大于女性平均用药剂量,有显著性差异(P=-0.034<0.05)。结论首发精神分裂症患者男女用药剂量不一样,女性患者平均用药剂量较小。

Objective To find out gender differences of sulpiride in the treatment of first--episode schizophrenia. Methods 71 first-onset schizophrenes were divided into two groups according to the gender, and use the positive and negative symptoms scales and side effects scale to assess the curative effect and the side reaction. Results The result shows that both groups＇ PANSS grades have significant difference before and after administering medicine, and the dosage mean of male group is more than tbat of female group （P=0. 034〈0.05）. Conclusion There were signilicantly differences with sulpiride in the treatment of first--epsode schizophrenia between the female and the male, the dosage mean of female is littler.